<DOC>
	<DOC>NCT01986933</DOC>
	<brief_summary>To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy</brief_summary>
	<brief_title>A Phase 2 Study of CIM331 for Atopic Dermatitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>≥18 and ≤65 years of age at the time of consent. Patients with Atopic Dermatitis Pruritus visual analogue scale (VAS) ≥50 mm at the screening and baseline visit Eczema Area and Severity Index (EASI) ≥10 at the screening and baseline visit static Investigator's Global Assessment (sIGA) score ≥3 at the baseline visit Serological evidence of hepatitis B virus or hepatitis C virus infection Known human immunodeficiency virus infection Ongoing treatment with specific or nonspecific hyposensitization therapy for AD Treatment with mild or moderately potent topical corticosteroids (TCS) within 1 week prior to randomization History of infection including skin infection requiring treatment with oral or intravenous (IV) antibiotics, antivirals, or antifungals within 1 week prior to randomization. Evidence of tuberculosis (TB) infection as defined by a positive purified protein derivative (PPD) and/or positive interferongamma release assay. Pregnant or lactating women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>